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A B S T R A C T
Background: Serum beta 2-microglobulin (B2M) levels have been found to be increased 
in patients with peripheral arterial disease (PAD), yet it is still unknown whether B2M 
correlates with PAD intensity. 
Objectives: We aim to evaluate the correlation between B2M and the ankle-brachial index 
(ABI) values in high-vascular-risk patients.
Methods: This is a cross-sectional study of 63 high-vascular-risk patients admitted to the 
Cardiology Department or evaluated as outpatients in the Internal Medicine Department 
of our institution. Patients were classified into two groups according to their ABI: patients 
without PAD (n = 44, ABI values between 0.9 and 1.4) and patients with PAD (n = 19, 
ABI values lower than 0.9 or higher than 1.4). We performed univariate and multivariate 
analysis based on a multiple linear regression model.
Results: Serum B2M levels were higher in patients with pathological ABI values than in 
those without PAD (2.36 ± 1.13 vs. 1.80 ± 0.65 mg/L; P<0.05). We found no correlation 
between B2M and ABI in our total population (r = –0.12) or in patients with PAD (r = 
–0.09; NS for both comparisons). Age, gender, arterial hypertension, estimated glomerular 
filtration rate (eGFR), uric acid, total cholesterol, and LDL-cholesterol correlated with 
B2M in the univariate analysis. In the final linear regression model, eGFR, uric acid and 
total cholesterol correlated independently with B2M (P<0.01). 
Conclusion: We found no correlation between B2M levels and ABI values in high-vascular-
risk patients that could usefully help in the subsequent diagnosis of PAD. However, we 
observed a significant correlation between B2M and eGFR, even when renal function was 
only slightly impaired. 
►Implication for health policy/practice/research/medical education:
Serum beta 2-microglobulin may be a useful marker of impaired renal function in high-vascular risk patients. However, its role as a biomarker in 
vascular risk stratification must still be clarified.
►Please cite this paper as:
Real de Asúa D, Puchades R, García-Polo I, Suárez C. A Study on the Relationship between Serum Beta 2-Microglobulin Levels, Underlying 
Chronic Kidney Disease, and Peripheral Arterial Disease in High-Vascular-Risk Patients. Int Cardiovasc Res J.2012;6(4):107-112.
1. Background
Atherosclerosis is the main pathophysiological substrate 
of cardiovascular disease, the leading cause of morbidity 
and mortality in developed countries (1). Peripheral arterial 
disease (PAD) is one of the most common manifestations 
of atherosclerosis (2). Its prevalence increases with age 
and the presence of concomitant vascular risk factors, 
and it can affect as many as 25% of high-vascular-risk 
patients (3). Diagnosing PAD can prove challenging, since 
most patients are asymptomatic and the combination of a 
thorough clinical history and detailed physical examination 
is not sufficiently sensitive to identify asymptomatic 
patients (4-6).
The ankle-brachial index (ABI) is a simple and 
inexpensive tool for assessing vascular permeability in 
the lower limbs and has proven to be the most accurate, 
practical, and effective method to date for diagnosing PAD 
(7). However, it is limited by its inter-observer variability, 
which increases in conditions such as critical lower 
extremity ischemia (8). Moreover, its application is time-
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consuming, and primary care practitioners usually lack the 
specialized equipment and trained personnel to perform 
ABI measurements in the office setting.
Interest in the use of plasma proteins to better stratify 
vascular risk has been growing during the last decade. 
These molecules would not only help to manage patients 
with moderate vascular risk, but could also be useful 
prognostic markers (9,10). Beta 2-microglobulin (B2M) 
is a low-molecular-weight polypeptide of the major 
histocompatibility complex class I molecule on the surface 
of all nucleated cells, and can be found in body fluids 
under physiological conditions (11). Since the molecule is 
filtered at the glomerulus (95%) and avidly reabsorbed at 
the proximal tubule (99%), plasma B2M levels depend on 
their production rate and the patient’s glomerular filtration 
rate (GFR) (12-14). The rate of production of B2M can 
increase significantly in active neoplasms, infections, or 
autoimmune diseases (15, 16).  Serum B2M levels are also 
elevated in patients with increased arterial stiffness and in 
patients with PAD due to several factors, such as declining 
renal function, repeated bouts of ischemia and reperfusion 
in the legs, and vascular inflammation (17,18). 
It is still unclear whether B2M could be a useful marker 
for PAD and thus identify candidates to be evaluated by 
ABI (19). This strategy could increase the pretest positive 
likelihood ratio of the ABI and facilitate its implementation 
in the office setting. Early recognition of PAD could trigger 
intensive risk factor modification with different treatments 
(20). The present study aims to evaluate the correlation 
between serum B2M levels and the diagnosis of PAD 
according to ABI values in a cohort of high-vascular-risk 
patients.
2. Materials and Methods
2.1. Study design
This is a cross-sectional study on high-vascular-risk patients 
from two different populations recruited consecutively 
on a 1:1 ratio, which included patients admitted to the 
Cardiology Department, and patients evaluated at the 
Vascular Risk outpatient clinic of the Internal Medicine 
Department, both at Hospital Universitario La Princesa in 
Madrid, Spain. The recruitment period ran from January 
2008 to June 2009. The study was conducted in accordance 
with the provisions of the Declaration of Helsinki and 
Good Clinical Practice guidelines. All patients provided 
their consent before any study procedure was performed.
2.2. Patients
Patients older than 40 years with grade 3 hypertension, 
three or more vascular risk factors, metabolic syndrome, 
diabetes mellitus or proven subclinical organ damage per 
review of their medical history were eligible for inclusion. 
All patients were recorded as having high vascular risk 
according to the directives of the European Society of 
Hypertension (21). Metabolic syndrome was defined 
according to the National Cholesterol Education Program 
(Adult Treatment Panel III)criteria (22). Patients with 
active cancer, with GFR lower than 30 mL/min, or with 
a previous kidney transplant, as well as those with HIV or 
any other acute infection, were excluded from the study, 
since these conditions are known to substantially modify 
B2M levels(12, 15, 16). GFR was estimated (eGFR) using 
the 4-variable Modification of Diet in Renal Disease 
equation (MDRD-4) (23).
The diagnosis of PAD was based on the numerical result 
of each patient’s ABI in accordance with the guidelines 
of the Inter-Society Consensus for the Management of 
Peripheral Arterial Disease (TASC II) (2). Further imaging 
tests were not performed to confirm the diagnosis of PAD. 
Patients were classified into two groups according to their 
ABI. This included patients without PAD, with ABI values 
between 0.9 and 1.4, and patients with PAD, with ABI 
values lower than 0.9 or higher than 1.4. Since patients with 
ABI higher than 1.4 also have an increased cardiovascular 
risk, which is considered equivalent to that of patients with 
ABI lower than 0.9, both were included in the same group 
for the final analysis (24-27).
2.3. ABI Measurement Technique
Before measurements were taken, patients were asked 
to lie for two to three minutes with their head raised to 
45º. Blood pressure (BP) in the arms was measured using 
an automated oscillometric device (OMRON-M6, Omron 
Healthcare, Vernon Hills, Illinois, USA). Three consecutive 
measurements were taken in both arms separated by one to 
two minute intervals. Only the results from the arm with 
the highest BP were used for the ABI determination. BP 
in the legs was measured using an 8-MHz duplex device 
(Huntleigh-SD2, Huntleigh Healthcare Ltd., Cardiff, UK). 
Three consecutive measurements separated by one to two 
minute interval were taken at the level of the posterior tibial 
and dorsalis pedis arteries of both ankles. To determine BP 
in the lower limbs, the average of the second and third 
measurements were used at each location. The highest 
systolic BP in each ankle was selected as the numerator for 
the ABI of that limb. The first BP measurement in the arm 
with the highest BP was selected as the denominator for the 
ABI. All ABI determinations were performed by the same 
two professionals, with experience in more than 30 ABI 
determinations prior to the beginning of the present study.
2.4. Beta 2-Microglobulin Measurement
Blood samples were collected from study subjects after 10-
hour overnight fast. Serum was obtained by centrifugation 
(1500 g for 15 min), transferred into coded plastic tubes, 
rapidly frozen and stored at -20 ºC until analysis. B2M 
was measured using ORG 5 BM immunoassay (Orgentec 
Diagnostica GmbH, Germany). The intra-assay and inter-
assay coefficients of variation were less than 3.6% and 
4.9%, respectively.
2.5. Statistical Analysis
All data were processed using SPSS (SPSS 20.0.0, IBM 
Corp., Armonk, New York, USA) and GraphPad Prism 
software (GraphPad Software, San Diego, California, USA). 
Qualitative results are presented as absolute frequencies 
(percentages), whereas quantitative results are presented 
as means ± standard deviations (SD). Non-parametric tests 
were used when appropriate. We performed univariate 
and multivariate analysis using multiple linear regression 
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to identify variables that correlated independently with 
B2M. Values exceeding the mean ± 2SD in the correlation 
analysis were considered outliers and were excluded. 
Variables whose statistical significance was lower than 
0.1 in the univariate analysis were included in the final 
multivariate analysis. For the remaining results, P values 
less than 0.05 were considered significant. All statistical 
tests were two-tailed.
3. Results
3.1. Baseline characteristics
The study population included 63 patients recruited 
between January 2008 and June 2009. Baseline 
characteristics, including coexisting conditions, are 
presented in Table 1. Hypertension and dyslipidemia were 
the most prevalent vascular risk factors in both groups, and 
the coronary arteries were the most frequently damaged 
vascular territory. Patients with PAD (19/63 patients, 
30%) were older, mostly females, with lower body mass 
index (BMI), suffered predominantly from type 2 diabetes 
mellitus (DM2), and had had an event in more vascular 
territories than patients without PAD. All patients were 
receiving antihypertensive and lipid-lowering medication 
during the study period.
The baseline analytical values of the study population are 
presented in Table 2. According to to the National Kidney 
Foundation criteria 23 patients (36%) had eGFR values 
>90 mL/min, 22 (35%) had eGFR values between 60 and 
90 mL/min, and 15 patients (24%) had stage 3 CKD (22). 
Patients with PAD had significantly lower eGFR (58 ± 17 
vs. 85 ± 25 mL/min, dif. means –27 ± 38 mL/min, 95%CI 
[–16.4 to –37.6]; P<0.01) and higher B2M levels (2.36 ± 
1.13 vs. 1.80 ± 0.65 mg/L, dif. means 0.55 ± 0.26 mg/L, 
95%CI [0.01 - 1.10]; P<0.05) than patients without PAD.
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Baseline characteristics
Total Without PAD PAD P value
n = 63 n = 44 n = 19
Age (years) 65 ± 10.2 63 ± 10 71 ± 8 <0.01
Male gender, No. (%) 47 (75%) 37 (86%) 10 (53%) <0.05
Weight (kg) 81.1 ± 17.2 85.2 ± 19.2 74.5 ± 10 <0.05
BMI (kg/m2) a 29 ± 4.8 29.7 ± 5.2 27.1 ± 2.8 <0.05
                Normal weight 11 (17%) 6 (14%) 5 (26%) NS
                Overweight 25 (40%) 17 (39%) 8 (42%) NS
                Obese 21 (33%) 19 (43%) 2 (11%) <0.05
Systolic BP (mmHg) 131 ± 22 129 ± 22 134 ± 23 NS
Diastolic BP (mmHg) 73 ± 13 76 ± 13 65 ± 9 <0.05
Heart rate (bpm) 69 ± 12 70 ± 12 68 ± 11 NS
Smoking status
Non-smoker 18 (29%) 13 (30%) 5 (26%) NS
Previous smoker 10 (16%) 7 (16%) 3 (16%) NS
Active smoker 35 (56%) 24 (55%) 11 (58%) NS
Family history 12 (19%) 10 (23%) 2 (11%) NS
Arterial hypertension 55 (87%) 37 (84%) 18 (95%) NS
Dyslipidemia 51 (81%) 36 (82%) 15 (79%) NS
T2DM a 29 (46%) 17 (39%) 12 (63%) <0.05
Metabolic syndrome 38 (60%) 26 (59%) 12 (63%) NS
Hyperuricemia 26 (41%) 19 (43%) 7 (37%) NS
Ischemic coronary disease 40 (63%) 28 (64%) 12 (63%) NS
Cerebrovascular disease 9 (14%) 3 (7%) 6 (32%) <0.05
Multiple territories 19 (30%) 2 (5%) 16 (84%) <0.01
ABI 1.05 ± 0.38 1.09 ± 0.11 0.71 ± 0.17 <0.01
Abbreviations: PAD, peripheral arterial disease; BMI, body mass index; BP, blood pressure; T2DM: type 2 diabetes mellitus; NS, Non-significant.
a Normal weight, BMI between 18 and 25 kg/m2; Overweight, BMI between 25 and 30 kg/m2; Obese, BMI over 30 kg/m2.  
Table 1. Baseline Characteristics. Results Are Presented as Means ± SD or as n (%).
Total Without PAD PAD
P value Units
n = 63 n = 44 n = 19
Glucose 6.60 ± 2.16 6.44 ± 1.94 6.99 ± 2.66 NS mmol/L
Total cholesterol 4.25 ± 1.24 4.40 ± 1.32 3.86 ± 0.96 NS mmol/L
LDL-cholesterol 2.25 ± 1.01 2.36 ± 1.11 2.02 ± 0.73 NS mmol/L
HDL-cholesterol 1.22 ± 0.34 1.22 ± 0.34 1.19 ± 0.34 NS mmol/L
Triglycerides 1.60 ± 1.08 1.72 ± 1.24 1.34 ± 0.56 NS mmol/L
Uric acid 368.8 ± 95.2 327.1 ± 83.3 368.8 ± 101.1 NS mmol/L
Creatinine 88.4 ± 26.5 88.4 ± 26.5 97.24 ± 25.6 NS mmol/L
eGFR 85 ± 34 85 ± 25 58 ± 17 <0.01 mL/min
B2M 1.97 ± 0.86 1.80 ± 0.65 2.36 ± 1.13 <0.05 mg/L
Abbreviations:eGFR, estimated glomerular filtration rate; B2M, beta 2-microglobulin; NS, non-significant
Table 2. Baseline Analytical Values in the Study Population. Results Are Presented as Mean ± SD.
3.2. Correlation between Serum B2M Levels and ABI 
Values
The correlation between B2M and ABI was assessed in 
55 patients. Eight subjects with outlying values of B2M 
were excluded from the analysis. No significant correlation 
between B2M and ABI values was found in our total 
population (Figure 1, r = –0.12; not significant), nor in 
patients with PAD (r = –0.09; not significant).
In the univariate analysis, serum B2M levels correlated 
with age (r=0.49; P<0.01), femaleness (2.58 vs. 1.76 
mg/L, dif. means 0.82 ± 0.31 mg/L, 95%CI [0.16 - 1.48]; 
P<0.05), arterial hypertension (2.05 vs. 1.44 mg/L, dif. 
means 0.61 ± 0.13 mg/L, 95%CI [0.35 - 0.87]; P<0.01), 
and plasma uric acid levels (r = 0.40; P<0.01). B2M 
showed an inverse strong correlation with eGFR (Figure 2, 
r = –0.62; P<0.01), and a fair one with total cholesterol (r = 
–0.31; P<0.05), and LDL-cholesterol (r = –0.27; P<0.05). 
Additionally, two variables approached a statistically 
significant correlation with B2M and were included in 
the final regression model, namely, family history of early 
vascular events (P=0.055) and type 2 diabetes mellitus 
(P=0.07). A statistically significant association was 
observed between gender and eGFR values, as the latter 
were significantly lower in women (64.7 vs. 92.3 mL/min, 
dif. means  –27.6 ± 9.4 mL/min, 95%CI [–8.8 to –46.4]; 
P<0.01). No other relevant associations were observed. 
The multivariate analysis is presented in Table 3. Serum 
B2M levels independently correlated with femaleness, 
uric acid, total cholesterol, and eGFR (ANOVA F 10.49; 
P<0.01). The adjusted R2 value for the model was 0.62. 
4. Discussion
We found no correlation between B2M levels and ABI 
values in high-vascular-risk patients that could usefully 
help in the subsequent diagnosis of PAD. However, the 
results of this study show a significant correlation between 
serum B2M levels and eGFR, even when renal function is 
only slightly impaired.  
To our knowledge, two other studies have specifically 
addressed this issue. Wilson et al. were the first to reveal 
a correlation between ABI and B2M (18). Although our 
main results disagree with their findings, their analysis 
of the correlation between B2M and ABI did not exclude 
outliers. Several other works have also disputed the initial 
findings of these authors. Our results agree with those of 
Kals et al., who found no association between B2M or 
pulse wave velocity and ABI in a population similar to 
that of our study (17). Busti et al. found no changes in 
B2M levels in PAD patients after exercise on a treadmill, 
thus challenging the initial hypothesis by Wilson et al. of 
an increase in B2M levels in patients with PAD due to 
repeated bouts of ischemia-reperfusion (28). 
Estimated GFR values were independently correlated 
with B2M levels in the regression analysis of the above-
mentioned studies (17,18). The relationship between 
serum B2M levels and GFR is well documented. End-stage 
chronic kidney disease (CKD) leads to accumulation of 
B2M in peripheral tissues, which is an established cause of 
systemic amyloidosis in patients undergoing dialysis (29). 
The present results prove that this relationship exists even 
in the normal range of GFR. Although over 70% of our 
patients had normal or mildly impaired eGFR, this variable 
still had the strongest correlation with B2M. Moreover, the 
significant influence of gender (female) on B2M levels 
observed in our study was also mediated by a lower eGFR. 
The relationship between eGFR and B2M has also been 
described in other clinical settings, such as HIV infection, 
diabetes mellitus, and glomerulonephritis (30-33).  
There is increasing evidence of the role of hyperuricemia 
in vascular damage, not only in the pathogenesis of 
hypertension, but also in metabolic syndrome and CKD 
(34). We interpreted the correlation between B2M and 
uric acid as a new indirect sign of the relationship between 
hyperuricemia and vascular risk. Surprisingly, we did not 
find type 2 diabetes mellitus to be significantly associated 
with B2M in our final multivariate model. The high burden 
of concomitant vascular risk factors could have accounted 
for a lower proportional significance of diabetes as a risk 
factor for PAD in these patients. Furthermore, the fact 
that other well-known risk factors, such as hypertension 
or smoking, were not found to be more prevalent in 
patients with PAD than in those without this diagnosis 
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B2M, beta 2-microglobulin; ABI, ankle-brachial index.
B2M, beta 2-microglobulin; eCCr, estimated creatinine 
clearance.
Figure 1. Correlation between Serum Beta 2-Microglobulin 
Levels and Ankle-Brachial Index in High-Vascular-Risk Patients
Figure 2. Correlation between Serum Beta 2-Microglobulin and 
Estimated Gomerular Filtration Rate in Patients with A High 
Vascular Risk
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also underlines the high overall vascular risk of the study 
subjects. This effect was also observed in the largest study 
to date, which considered B2M as a marker for stratifying 
mortality in an elderly population, where Shinkai et al., 
found no significant correlation between B2M levels and 
the presence of DM2 after multiple statistical corrections 
for possible confounders (19). Given these results, which 
point to a non-specific elevation of B2M in patients with a 
high vascular risk, we agree with other authors that B2M 
levels may not indicate the presence of PAD, but may 
reflect an increased burden of systemic atherosclerosis in a 
setting of underlying CKD (14,17).
Our study is supported by a number of strong points. All 
the patients had a high vascular risk, even though not all 
of them had presented a vascular event at the time of the 
study. Prompt diagnosis of exacerbating factors is most 
needed in high-risk patients. All ABI determinations were 
performed by the two same professionals, thus diminishing 
potential inter-observer variability. The limitations of our 
study are mainly technical. ABI was determined using a 
mixed technique (oscillometric automated device for the 
arms and a duplex device for the legs). Small differences 
in measurements between the devices may have altered the 
final numerical value of the ABI. We did not apply a gold 
standard for GFR determination, and the estimation of this 
parameter with the MDRD-4 equation is slightly inaccurate 
for GFR values over 60 mL/min (35). The National Kidney 
Foundation also encourages its use over plasma creatinine 
levels across the complete range of GFR values (23), and 
estimated GFR with the MDRD-4 equation has been used 
to assess GFR in a number of authoritative studies (36-38). 
The use of ABI as the sole diagnostic tool to assess PAD 
may have minimally underestimated the real prevalence 
of the disease in our high-vascular-risk setting. Finally, 
the exclusion of patients with an eGFR below 30 mL/
min and those with outlying values of B2M could have 
partially induced a bias to the null. However, it is precisely 
in patients with end-stage CKD in whom the correlation 
between B2M and eGFR has already been best described 
(12-14). Thus, the possible additional influence of other 
vascular risk factors on that correlation would probably be 
proportionally less significant.  
It is still unknown whether the use of B2M as a biomarker 
could add any additional information to the classic models 
of vascular risk stratification, which are based on simpler 
clinical and analytical parameters, especially in patients 
with moderate vascular risk. Other biomarkers face similar 
challenges (9). To sum up, we failed to find a correlation 
between B2M levels and ABI values in high-vascular-risk 
patients that could usefully help in the subsequent diagnosis 
of PAD. However, we show a significant correlation 
between serum B2M levels and eGFR throughout the 
complete range of renal function values down to a lower 
cut-off value of 30 mL/min.
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